Document is current
Any future updates will be listed below
-
Authors
Ysselstein, Daniel
Nguyen, Maria
Young, Tiffany J.
Severino, Alex
Schwake, Michael
Merchant, Kalpana
Krainc, Dimitri
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (T32NS041234)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (2T32AG020506-16)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (RO1 NS076054)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R37 NS096241)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Michael J. Fox Foundation for Parkinson's Research (13635)
- License Information
-
More Information
Article History
Received: 20 March 2019
Accepted: 7 November 2019
First Online: 5 December 2019
Competing interests
: D.K. is a scientific advisor for Prevail Therapeutics and Intellia Therapeutics, as well as a venture partner at Orbimed. D.Y., M.N., T.Y., A.S., M.S., and K.M. declare no competing interests.
